Company: 

Adaptimmune

Adaptimmune

NST provided quality review for a broad range of regulatory documents, including:

  • Investigator’s Brochures
  • Development Safety Update Reports
  • Clinical Study Reports
  • Patient safety and efficacy narratives

We were also contracted to provide medical writing and editorial support as well as general QX function for all regulatory submission documents.

What our client said

"“I cannot praise the Niche team highly enough, having been a huge support from the outset – we quickly built up a great relationship, they are very supportive, responsive to all my emails and incredibly approachable and friendly. They have made it clear that they are always there when we need them."

photophotophotophotophoto

Dr Sarah Loftus, Associate Director, Medical Writing

Adaptimmune




Project background
Founded in 2008, Adaptimmune specialises in developing novel therapies for the treatment of resistant tumour types, exploiting their proprietary cell therapy platform which harnesses a patient's own cells. Adaptimmune engineers the patient’s T-cell receptors (TCRs) so that they identify cancer proteins for target therapy. The company received US FDA approval for TECELRA® in 2024, becoming the first engineered cell therapy for solid tumour cancers. The company has since been researching multiple novel therapies for a variety of cancer types.
Delivery

NST began work with Adaptimmune in 2024, conducting a QC review of an IB update for uzatresgene autoleucel, one of Adaptimmune’s TCR-based therapies. NST went onto play a pivotal role with the team responsible for the delivery of Adaptimmune’s regulatory documents. Adaptimmune appreciated NST’s flexibility and range of skills, meaning assistance could be scaled to address any of their medical writing needs across a broad range of regulatory documents for their various development assets.

NST established clear lines of communication with the Adaptimmune team to enable close tracking of multiple documents across a variety of projects with ambitious timelines. All documents were delivered to the highest quality and according to the agreed timelines.

Related Case studies

Medical writing

Specialising in the discovery and development of small-molecule drugs for oncology and central nervous system disorders.

Niche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study.

read more
Medical writing

The FRAILOMIC initiative was an international research project

Niche built and coordinated the full communications strategy for this 20-institution European initiative, turning.

read more
Medical writing

BSH is the UK’s largest haematology organisation, promoting excellence within the field and supporting professional development.

Over a decade and 20+ guidelines later, Niche remains the BSH's trusted partner for raising haematology care standards.

read more
Medical writing

Cleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic solutions.

When stalled regulatory documentation threatened to derail their neurological programme, Cleothena turned to Niche —.

read more
Medical writing

Nabriva Therapeutics is committed to developing new antibiotics to treat infectious diseases.

Niche supported Nabriva's antibiotic lefamulin from early clinical protocols all the way to FDA, EMA and Health Canada.

read more
Medical writing

A specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription medicines.

Putting patients first, Niche supported ViiV Healthcare's global HIV outreach programmes with medical writing,.

read more
Medical writing

Partnership with a clinical research organisation specialising in comprehensive data services for clinical trials.

For over a decade, Assign DMB relied on Niche as their embedded writing partner, seamlessly converting statistical.

read more
Medical writing

Providing regulatory and medical writing support to meet client needs

Niche served as the English-language regulatory writing backbone for this Nordic consultancy, producing IBs, IMPDs and.

read more

Get our latest news and publications

Sign up to our news letter

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility